EcoDrugPlus

Gamma-Aminobutyric Acid Type A Receptor Subunit Beta3

Ensembl ID : ENSBBBG00000009697
Gene Symbol: GABRB3
3 Cross references
256 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Delta

Ensembl ID : ENSBBBG00000004342
Gene Symbol: GABRD
3 Cross references
194 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma1

Ensembl ID : ENSBBBG00000019154
Gene Symbol: GABRG1
3 Cross references
189 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma2

Ensembl ID : ENSBBBG00000008528
Gene Symbol: GABRG2
3 Cross references
206 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma3

Ensembl ID : ENSBBBG00000009677
Gene Symbol: GABRG3
1 Cross references
239 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Pi

Ensembl ID : ENSBBBG00000000159
Gene Symbol: GABRP
3 Cross references
125 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 1

Ensembl ID : ENSBBBG00000008367
Gene Symbol: GABBR1
3 Cross references
267 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 2

Ensembl ID : ENSBBBG00000019081
Gene Symbol: GABBR2
3 Cross references
208 Possible Orthologues:

Gastric Inhibitory Polypeptide Receptor

Ensembl ID : ENSBBBG00000000834
Gene Symbol: GIPR
3 Cross references
93 Possible Orthologues:

Glucagon Like Peptide 1 Receptor

Ensembl ID : ENSBBBG00000002536
Gene Symbol: GLP1R
3 Cross references
133 Possible Orthologues:

Glucagon Like Peptide 2 Receptor

Ensembl ID : ENSBBBG00000002641
Gene Symbol: GLP2R
3 Cross references
205 Possible Orthologues:

Glucagon Receptor

Ensembl ID : ENSBBBG00000015780
Gene Symbol: GCGR
3 Cross references
184 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).